Evidence map›Paper›PMID 18989656›Full record

ArticleIntensive care medicine2009

Defining, treating and preventing hospital acquired pneumonia: European perspective.

Antoni Torres, Santiago Ewig, Harmut Lode, Jean Carlet, European HAP working group

2 registry-linked trialsAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Intensive care medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 77 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02019420 phase3completednot on this mapstarted 2014, after this paper: background citation

A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia

TypeinterventionalSponsorCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Ran2014 to 2018Enrolled726ConditionsPneumoniaArmsTedizolid phosphate, Linezolid
NCT03039998 completednot on this mapstarted 2013, after this paper: background citation

Validity of Biological Material Sampling in Patients With Hospital-acquired Pneumonia

TypeobservationalSponsorUniversity Hospital OlomoucRan2013 to 2015Enrolled56ConditionsHospital Acquired Pneumonia
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Impact of selective digestive decontamination on respiratory tract Candida among patients with suspected ventilator-associated pneumonia. A meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016
    Pooled it
  3. Ventilator-associated pneumonia: current status and future recommendations.Journal of clinical monitoring and computing · 2010
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Ventilator-associated pneumonia with or without toothbrushing: a randomized controlled trial.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012
    Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Antoni TorresCap de Servei de Pneumologia i Al.lèrgia Respiratòria. Institut Clínic del Tòrax, Hospital Clínic de Barcelona, Universitat de Barcelona. IDIBAPS.CIBERES 06/06/0028., C/ Villarroel, 170, 08036, Barcelona, Spain. atorres@ub.edu
Santiago Ewig
Harmut Lode
Jean Carlet
European HAP working group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMany controversies still remain in the management of hospital acquired pneumonia (HAP), and ventilation-acquired pneumonia (VAP), Three European Societies, European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and European Society of Intensive Care Medicine (ESICM), were interested in producing a document on HAP and VAP with European perspective. MATERIALS AND

methodsThe scientific committees from each Society designated one chairman; Antoni Torres (ERS), Harmut Lode (ESCMID) and Jean Carlet (ESICM). The chairmen of this Task Force suggested names from each Society to be a member of the panel. They also choose controversial topics on the field and others that were not covered by the last IDSA/ATS guidelines. Each topic was assigned to a pair of members to be reviewed and written. Finally, the panel defined 20 consensual points that were circulated several times among the members of the panel until total agreement was reached. A combination of evidences and clinical-based medicine was used to reach these consensus.

conclusionThis manuscript reviews in depth several controversial or new topics in HAP and VAP. In addition 20 consensual points are presented. This manuscript may be useful for the development of future guidelines and to stimulate clinical research by lying out what is currently accepted and what is unknown or controversial.

Indexed as

Anti-Bacterial AgentsHumansPneumonia, BacterialPneumonia, Ventilator-AssociatedTracheostomyAnti-Bacterial Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.